Biocryst Pharmaceuticals (BCRX) Revenue (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has reported Revenue for 17 consecutive years, with $218.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 33.61% year-over-year to $218.2 million; the trailing twelve-month figure through Jun 2026 stood at $534.8 million (down 4.08% YoY), and the FY2025 full-year result was $874.8 million, up 94.1% from the prior year.
• Revenue rose to $218.2 million in Q2 2026 per BCRX's latest filing, from $156.4 million in the prior quarter.
• Across five years, Revenue topped out at $218.2 million in Q2 2026 and bottomed at $708000.0 in Q4 2025.
• Historically, Revenue has averaged $105.4 million across 5 years, with a median of $93.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Revenue soared 161.94% in 2022, then slumped 99.46% in 2025.
• Over 5 years, Revenue stood at $79.5 million in 2022, then rose by 17.42% to $93.4 million in 2023, then soared by 40.83% to $131.5 million in 2024, then plunged by 99.46% to $708000.0 in 2025, then surged by 30726.27% to $218.2 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $218.2 million, $156.4 million, and $708000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.